|Mr. David Alan Dodd||Chairman, Pres & CEO||381.5k||N/A||1950|
|Mr. Mark W. Reynolds CPA, CPA||CFO & Corp. Sec.||339.99k||N/A||1962|
|Dr. Mark J. Newman Ph.D.||Chief Scientific Officer||175k||N/A||1955|
|Dr. Harriet Latham Robinson||Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board||N/A||N/A||1938|
|Dr. Kelly T. McKee Jr., M.D., M.P.H.||Chief Medical Officer||N/A||N/A||1950|
|Jeffrey Welch||Head of Process Devel. & Manufacturing Operations||N/A||N/A||N/A|
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
GeoVax Labs, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.